Study: NCT01897389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions